There were no T cell-jolting developments, but new ground was broken at the prestigious eighth-annual Conference on Retroviruses and Opportunistic Infections in Chicago in February. Tongues were wagging about antiretrovirals -- good results with new classes, including fusion inhibitors and chemokine attackers, and with side-effect reduction -- a new Bristol Myers protease inhibitor (BMS-232632) is potent but doesn’t raise blood fats. POZ will keep you posted, as these advances develop (or not) into solutions for lipodystrophy and drug resistance. Meanwhile, eyeball the hot type below.
Conference on Retroviruses and Opportunistic Infections